DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1362 Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment
of mild to moderate active Crohn’s ileitis: Results of a
randomized, multicenter trial. Gastroenterology, 1999,
116:521–526.
Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-
mercaptopurine for induction of remission in Crohn’s disease.
Cochrane Database Syst Rev, 2009, CD000545.
Preidis GA, Versalovic J. Targeting the human microbiome with
antibiotics, probiotics, and prebiotics: Gastroenterology enters
the metagenomics era. Gastroenterology, 2009, 136: 2015–2031.
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment
of fistulas in patients with Crohn’s disease. N Engl J
Med, 1999, 340:1398–1405.
Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for
inflammatory bowel disease. Gastroenterology, 2009, 136:
1182–1197.
Rutgeerts P, Feagan BF, Lichtenstein GR, et al. Comparison of
scheduled and episodic treatment strategies of infliximab in
Crohn’s disease. Gastroenterology, 2004, 126:402–413.
Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole
treatment for prevention of Crohn’s recurrence after
ileal resection. Gastroenterology, 1995, 108:1617–1621.
SECTION VI
Salzmann NH, Bevins CL. Negative interactions with the microbiota:
IBD. Adv Exp Biol Med, 2008, 635:67–78.
Sandborn WJ. A critical review of cyclosporine therapy in
inflammatory bowel disease. Inflamm Bowel Dis, 1995, 1:
48–63.
Sands BE, Anderson, FH, Bernstein CN, et al. Infliximab maintenance
therapy for fistulizing Crohn’s disease. N Engl J Med,
2004, 350:876–885.
Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for
maintenance of remission in Crohn’s disease. Cochrane
Database Syst Rev, 2003, CD000301.
Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory
bowel disease. J Clin Invest, 2007, 117:514–521.
Sutherland L, Singleton J, Sessions J, et al. Double blind,
placebo- controlled trial of metronidazole in Crohn’s disease.
Gut, 1991, 32:1071–1075.
Targan SR, Hanauer SB, van Deventer SJ, et al. A short- term
study of chimeric monoclonal antibody cA2 to tumor necrosis
factor alpha for Crohn’s disease. N Engl J Med, 1997, 337:
1029–1035.
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of
inflammatory bowel disease. Nature, 2007, 448: 427–434.
DRUGS AFFECTING GASTROINTESTINAL FUNCTION